A number of other analysts also recently issued reports on the company. Zacks Investment Research downgraded Catalent from a buy rating to a hold rating in a research report on Friday, September 1st. Bank of America Corporation reissued a buy rating and set a $38.00 price objective (up from $37.00) on shares of Catalent in a research report on Friday, July 21st. Piper Jaffray Companies reissued a buy rating and set a $45.00 price objective on shares of Catalent in a research report on Tuesday, August 29th. William Blair reissued an ourperform rating on shares of Catalent in a research report on Tuesday, August 29th. Finally, BidaskClub downgraded Catalent from a strong-buy rating to a buy rating in a research report on Tuesday, June 27th. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $36.80.
Catalent (NASDAQ CTLT) opened at 40.79 on Tuesday. The firm’s 50-day moving average is $36.39 and its 200-day moving average is $33.25. Catalent has a 52-week low of $21.83 and a 52-week high of $42.22. The company has a market cap of $5.11 billion and a PE ratio of 46.89.
Catalent (NASDAQ:CTLT) last issued its quarterly earnings data on Monday, August 28th. The company reported $0.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.08. The firm had revenue of $616.90 million during the quarter, compared to the consensus estimate of $547.48 million. Catalent had a return on equity of 16.95% and a net margin of 4.88%. The company’s quarterly revenue was up 15.9% on a year-over-year basis. During the same period last year, the company earned $0.52 EPS. On average, equities research analysts anticipate that Catalent will post $1.60 EPS for the current year.
In other news, SVP Christine Dolan sold 1,594 shares of the business’s stock in a transaction dated Tuesday, August 29th. The stock was sold at an average price of $38.75, for a total transaction of $61,767.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Institutional investors have recently made changes to their positions in the company. Acrospire Investment Management LLC grew its position in shares of Catalent by 72.2% during the second quarter. Acrospire Investment Management LLC now owns 3,100 shares of the company’s stock worth $109,000 after buying an additional 1,300 shares in the last quarter. Quantbot Technologies LP grew its position in shares of Catalent by 110.7% during the second quarter. Quantbot Technologies LP now owns 3,434 shares of the company’s stock worth $120,000 after buying an additional 1,804 shares in the last quarter. Flinton Capital Management LLC grew its position in shares of Catalent by 17.7% during the first quarter. Flinton Capital Management LLC now owns 3,616 shares of the company’s stock worth $102,000 after buying an additional 544 shares in the last quarter. Meadow Creek Investment Management LLC grew its position in shares of Catalent by 17.7% during the first quarter. Meadow Creek Investment Management LLC now owns 4,972 shares of the company’s stock worth $141,000 after buying an additional 748 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Catalent by 12.5% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,043 shares of the company’s stock worth $177,000 after buying an additional 559 shares in the last quarter.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.